Michael Freeman

John Newman

Patrick Trucchio

Carvey Leung

Luis Santos

Michael Okunewitch

Rahul Sarugaser

Soumit Roy

- Oncolytics Biotech Inc. provided an updated safety analysis for **pelareorep**, an intravenously delivered double-stranded RNA immunotherapeutic agent.  **[1129928_0001129928-25-000072_oncypooledsafetypr.htm:0]** 
- The analysis, which includes data from **over 1,200 patients** dosed with pelareorep (including **over 300 gastrointestinal cancer patients**), continues to demonstrate a **favorable safety profile** across multiple indications and treatment combinations.  **[1129928_0001129928-25-000072_oncypooledsafetypr.htm:0]** 
- The most frequent adverse events observed were **Grade 1 and 2 flu-like symptoms** (fever, chills, fatigue) and gastrointestinal issues (nausea, vomiting, diarrhea), with **neutropenia** also noted in GI tumor patients.  **[1129928_0001129928-25-000072_oncypooledsafetypr.htm:0]** 
- The company's CEO stated that pelareorep represents **one of the most de-risked immunotherapies** not yet approved, and Oncolytics is moving towards **registration-enabled studies** and actively pursuing strategic partnerships.  **[1129928_0001129928-25-000072_oncypooledsafetypr.htm:0]**

ONCOLYTICS BIOTECH (ONCY)